TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Roth Affirms TG Therapeutics (TGTX) at 'Focus Pick'; Sees Strong Results in 2016
March 8, 2016 11:41 AM ESTRoth Capital reaffirms TG Therapeutics (Nasdaq: TGTX) with a Buy (and Focus Pick) rating and $33 price target following the company's FY15 results report, which was made late Monday.
Joseph Pantginis, Ph.D., commented, The GENUINE Phase III (under SPA) is now enrolling at >150 U.S. sites and complete enrollment is expected by year-end and top-line data in early 2017. TG... More
